Phase 1b, Multicenter, Open-Label Study of Marizomib Combined With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Marizomib (Primary) ; Temozolomide
- Indications Glioma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 11 Apr 2018 Planned number of patients changed from 60 to 72.
- 11 Apr 2018 Planned End Date changed from 31 Dec 2019 to 31 May 2020.
- 11 Apr 2018 Planned primary completion date changed from 18 Jun 2018 to 18 Jun 2019.